Cargando…

Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells

BACKGROUND: Multiple studies concluded that oncometabolites (e.g. D-2-hydroxyglutarate (2-HG) related to mutant isocitrate dehydrogenase 1/2 (IDH1/2) and lactate) have tumour promoting potential. Regulatory mechanisms implicated in the maintenance of oncometabolite production have great interest. mT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hujber, Zoltán, Petővári, Gábor, Szoboszlai, Norbert, Dankó, Titanilla, Nagy, Noémi, Kriston, Csilla, Krencz, Ildikó, Paku, Sándor, Ozohanics, Olivér, Drahos, László, Jeney, András, Sebestyén, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457553/ https://www.ncbi.nlm.nih.gov/pubmed/28578659 http://dx.doi.org/10.1186/s13046-017-0544-y

Ejemplares similares

GABA, glutamine, glutamate oxidation and succinic semialdehyde dehydrogenase expression in human gliomas
por: Hujber, Zoltán, et al.
Publicado: (2018)

Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells
por: Petővári, Gábor, et al.
Publicado: (2019)

Targeting cellular metabolism using rapamycin and/or doxycycline enhances anti-tumour effects in human glioma cells
por: Petővári, Gábor, et al.
Publicado: (2018)

The role of metabolic ecosystem in cancer progression — metabolic plasticity and mTOR hyperactivity in tumor tissues
por: Sebestyén, Anna, et al.
Publicado: (2022)

The oncometabolite 2-hydroxyglutarate produced by mutant IDH1 sensitizes cells to ferroptosis
por: Wang, Tian-Xiang, et al.
Publicado: (2019)

3D bioprinting and the revolution in experimental cancer model systems—A review of developing new models and experiences with in vitro 3D bioprinted breast cancer tissue-mimetic structures
por: Sztankovics, Dániel, et al.
Publicado: (2023)

Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations
por: Krencz, Ildiko, et al.
Publicado: (2021)

Rapamycin Plus Doxycycline Combination Affects Growth Arrest and Selective Autophagy-Dependent Cell Death in Breast Cancer Cells
por: Dankó, Titanilla, et al.
Publicado: (2021)

In Situ Metabolic Characterisation of Breast Cancer and Its Potential Impact on Therapy
por: Petővári, Gábor, et al.
Publicado: (2020)

The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo
por: Suijker, Johnny, et al.
Publicado: (2015)

Metabolic Adaptation as Potential Target in Papillary Renal Cell Carcinomas Based on Their In Situ Metabolic Characteristics
por: Krencz, Ildikó, et al.
Publicado: (2022)

Human Phosphoglycerate Dehydrogenase Produces the Oncometabolite d-2-Hydroxyglutarate
por: Fan, Jing, et al.
Publicado: (2014)

The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway
por: Carbonneau, Mélissa, et al.
Publicado: (2016)

The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas
por: Mu, Luyan, et al.
Publicado: (2018)

Characterisation of 3D Bioprinted Human Breast Cancer Model for In Vitro Drug and Metabolic Targeting
por: Dankó, Titanilla, et al.
Publicado: (2022)

Characterization of mTOR Activity and Metabolic Profile in Pediatric Rhabdomyosarcoma
por: Felkai, Luca, et al.
Publicado: (2020)

The Enzymology of 2-Hydroxyglutarate, 2-Hydroxyglutaramate and 2-Hydroxysuccinamate and Their Relationship to Oncometabolites
por: Hariharan, Vivek A., et al.
Publicado: (2017)

Another small molecule in the oncometabolite mix: L-2-Hydroxyglutarate in kidney cancer
por: Shim, Eun-Hee, et al.
Publicado: (2015)

Lactonization of the Oncometabolite D-2-Hydroxyglutarate Produces a Novel Endogenous Metabolite
por: Berger, Raffaela S., et al.
Publicado: (2021)

Characterisation of bioenergetic pathways and related regulators by multiple assays in human tumour cells
por: Jeney, A., et al.
Publicado: (2016)

Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells
por: Li, Luyuan, et al.
Publicado: (2015)

Human phosphoglycerate dehydrogenase produces the oncometabolite D-2-hydroxyglutarate and promotes histone methylation
por: Fan, Jing, et al.
Publicado: (2014)

The Emerging Role of D-2-Hydroxyglutarate as an Oncometabolite in Hematolymphoid and Central Nervous System Neoplasms
por: Rakheja, Dinesh, et al.
Publicado: (2013)

Registered report: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases
por: Evans, Brad, et al.
Publicado: (2015)

Imaging 2-hydroxyglutarate and other brain oncometabolites pertinent to critical genomic alterations in brain tumors
por: Thomas, Teena, et al.
Publicado: (2023)

Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Cells
por: Badur, Mehmet G., et al.
Publicado: (2018)

Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Cells
por: Badur, Mehmet G., et al.
Publicado: (2018)

The oncometabolite R-2-hydroxyglutarate dysregulates the differentiation of human mesenchymal stromal cells via inducing DNA hypermethylation
por: Liu, Lizhen, et al.
Publicado: (2021)

Oncometabolite D-2-hydroxyglutarate—dependent metabolic reprogramming induces skeletal muscle atrophy during cancer cachexia
por: Zhu, Xinting, et al.
Publicado: (2023)

Intracerebral Distribution of the Oncometabolite d-2-Hydroxyglutarate in Mice Bearing Mutant Isocitrate Dehydrogenase Brain Tumors: Implications for Tumorigenesis
por: Pickard, Amanda J., et al.
Publicado: (2016)

In Situ Analysis of mTORC1/C2 and Metabolism-Related Proteins in Pediatric Osteosarcoma
por: Mohás, Anna, et al.
Publicado: (2022)

Oncometabolite D-2-Hydroxyglutarate enhances gene silencing through inhibition of specific H3K36 histone demethylases
por: Janke, Ryan, et al.
Publicado: (2017)

Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma
por: Nakagawa, Makoto, et al.
Publicado: (2022)

Metabolomic analysis identifies differentially produced oral metabolites, including the oncometabolite 2-hydroxyglutarate, in patients with head and neck squamous cell carcinoma
por: Mukherjee, Pranab K., et al.
Publicado: (2016)

The oncometabolite R-2-hydroxyglutarate activates NF-κB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells
por: Chen, Jing-Yi, et al.
Publicado: (2016)

Accumulation of oncometabolite D-2-Hydroxyglutarate by SLC25A1 inhibition: A metabolic strategy for induction of HR-ness and radiosensitivity
por: Xiang, Kexu, et al.
Publicado: (2022)

A novel pathogenetic factor of laryngeal attack in hereditary angioedema? Involvement of protease activated receptor 1
por: Farkas, Henriette, et al.
Publicado: (2022)

2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated glioma patients
por: Choi, Changho, et al.
Publicado: (2012)

Cerebrospinal fluid 2-hydroxyglutarate as a monitoring biomarker for IDH-mutant gliomas
por: Riviere-Cazaux, Cecile, et al.
Publicado: (2023)

Survival of HT29 cancer cells is influenced by hepatocyte growth factor receptor inhibition through modulation of self-DNA-triggered TLR9-dependent autophagy response
por: Bohusné Barta, Bettina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ad8nslurtk01l85kn90mshg3vn